Chi Meng Fong
Stock Analyst at Bank of America Securities
(0.92)
# 3,707
Out of 5,162 analysts
50
Total ratings
35.7%
Success rate
-6.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chi Meng Fong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Reiterated: Hold | $41 → $42 | $40.67 | +3.27% | 31 | Nov 10, 2026 | |
| SUPN Supernus | Initiated Coverage: Buy | $47 | $27.62 | +70.17% | 1 | Nov 9, 2026 | |
| RLAY Relay Therapeutics | Reiterated: Buy | n/a | $20.39 | - | 8 | Nov 5, 2026 | |
| CCCC C4 Therapeutics | Rated: Hold | n/a | $3.15 | n/a | 5 | Oct 31, 2023 | |
| FHTX Foghorn Therapeutics | Rated: Hold | n/a | $2.04 | n/a | 5 | Oct 6, 2023 |
Roivant Sciences
Nov 10, 2026
Reiterated: Hold
Price Target: $41 → $42
Current: $40.67
Upside: +3.27%
Supernus
Nov 9, 2026
Initiated Coverage: Buy
Price Target: $47
Current: $27.62
Upside: +70.17%
Relay Therapeutics
Nov 5, 2026
Reiterated: Buy
Price Target: n/a
Current: $20.39
Upside: -
C4 Therapeutics
Oct 31, 2023
Rated: Hold
Price Target: n/a
Current: $3.15
Upside: n/a
Foghorn Therapeutics
Oct 6, 2023
Rated: Hold
Price Target: n/a
Current: $2.04
Upside: n/a